Raytheon Technologies’ chief financial officer said Wednesday the company, buoyed by news of progress on a COVID-19 vaccine, sees a return by passengers to air travel.
Shares of Raytheon Technologies Corp. jumped nearly 11 percent Monday after Pfizer and partner BioNTech said their vaccine against COVID-19 was strongly effective and exceeded expectations.
Indexes surged, with shares of other aviation companies also rising sharply. Boeing, for example, was up nearly 14 percent and General Electric jumped about 8 percent.
“We’re encouraged by the progress being made toward a safe and effective vaccine,” Toby O’Brien, chief financial officer of Raytheon Technologies, said in an online discussion with an industry analyst.
“We remain hopeful that a vaccine will be widely distributed, carving a path toward a return to public confidence and a normalization in air traffic.”
Raytheon Technologies is the parent company of Collins Aerospace, Cedar Rapids’ largest employer.
Still, he repeated what Waltham, Mass.-based Raytheon has said previously — that passenger travel is not expected to return to pre-COVID-19 levels until 2023.
ARTICLE CONTINUES BELOW ADVERTISEMENT
In addition, O’Brien said maintenance and repair of jet engines — a big part of business for Pratt and Whitney, another Raytheon unit — will lag by six to nine months.
“So I think that the answer is no, that our overall outlook and view hasn’t changed,” he said.
“Obviously, a vaccine is a step in the process.”
Raytheon sees a “gradual recovery” in its commercial aerospace businesses beginning in the current quarter, combined with an expected ramp-up at its Intelligence and Space and Missiles and Defense businesses, he said.
Plans to build a Pratt and Whitney advanced manufacturing plant for engine parts in Asheville, N.C., is “speaking to our confidence in the longer term” of aviation, O’Brien said.
Raytheon expects fourth-quarter sales of between $16.2 billion and $16.4 billion, in line with what Wall Street expects, according to Zacks Investment Research.
In addition, with $10 billion on hand as of Sept. 30, O’Brien said Raytheon has “got plenty of cash” and with the recovery that “has played out … largely as we expected,” the company will resume share buybacks next year.
The coronavirus is surging and a vaccine is at least months away. Still, O’Brien’s upbeat tone contrasts with negative news of layoffs, furloughs and other financial hits beginning in April, just weeks after the company was formed from the merger of United Technologies Corp. and Raytheon Co.
Support our coverage
Our most important Coronavirus coverage is free to the public.
If you believe local news is essential, especially during this crisis, please subscribe. Your subscription will support news resources to cover the impact of the pandemic on our local communities.
— to www.thegazette.com